602 related articles for article (PubMed ID: 21482669)
21. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
Dormond O; Contreras AG; Meijer E; Datta D; Flynn E; Pal S; Briscoe DM
J Immunol; 2008 Dec; 181(11):8088-95. PubMed ID: 19018001
[TBL] [Abstract][Full Text] [Related]
22. Critical role of SCD1 in autophagy regulation via lipogenesis and lipid rafts-coupled AKT-FOXO1 signaling pathway.
Tan SH; Shui G; Zhou J; Shi Y; Huang J; Xia D; Wenk MR; Shen HM
Autophagy; 2014 Feb; 10(2):226-42. PubMed ID: 24296537
[TBL] [Abstract][Full Text] [Related]
23. Fetal brain mTOR signaling activation in tuberous sclerosis complex.
Tsai V; Parker WE; Orlova KA; Baybis M; Chi AW; Berg BD; Birnbaum JF; Estevez J; Okochi K; Sarnat HB; Flores-Sarnat L; Aronica E; Crino PB
Cereb Cortex; 2014 Feb; 24(2):315-27. PubMed ID: 23081885
[TBL] [Abstract][Full Text] [Related]
24. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
[TBL] [Abstract][Full Text] [Related]
25. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
[TBL] [Abstract][Full Text] [Related]
26. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM
Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922
[TBL] [Abstract][Full Text] [Related]
27. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells.
Li C; Lee PS; Sun Y; Gu X; Zhang E; Guo Y; Wu CL; Auricchio N; Priolo C; Li J; Csibi A; Parkhitko A; Morrison T; Planaguma A; Kazani S; Israel E; Xu KF; Henske EP; Blenis J; Levy BD; Kwiatkowski D; Yu JJ
J Exp Med; 2014 Jan; 211(1):15-28. PubMed ID: 24395886
[TBL] [Abstract][Full Text] [Related]
28. Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways.
Wang S; Amato KR; Song W; Youngblood V; Lee K; Boothby M; Brantley-Sieders DM; Chen J
Mol Cell Biol; 2015 Apr; 35(7):1299-313. PubMed ID: 25582201
[TBL] [Abstract][Full Text] [Related]
29. FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor.
Chen CC; Jeon SM; Bhaskar PT; Nogueira V; Sundararajan D; Tonic I; Park Y; Hay N
Dev Cell; 2010 Apr; 18(4):592-604. PubMed ID: 20412774
[TBL] [Abstract][Full Text] [Related]
30. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
[TBL] [Abstract][Full Text] [Related]
31. mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes.
Eid S; Boutary S; Braych K; Sabra R; Massaad C; Hamdy A; Rashid A; Moodad S; Block K; Gorin Y; Abboud HE; Eid AA
Antioxid Redox Signal; 2016 Nov; 25(13):703-719. PubMed ID: 27393154
[TBL] [Abstract][Full Text] [Related]
32. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells.
Alayev A; Sun Y; Snyder RB; Berger SM; Yu JJ; Holz MK
Cell Cycle; 2014; 13(3):371-82. PubMed ID: 24304514
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of 14-3-3 binding to Rictor of mTORC2 for Akt phosphorylation at Ser473 is regulated by selenoprotein W.
Jeon YH; Park YH; Kwon JH; Lee JH; Kim IY
Biochim Biophys Acta; 2013 Oct; 1833(10):2135-42. PubMed ID: 23680186
[TBL] [Abstract][Full Text] [Related]
34. Rictor/mTORC2 protects against cisplatin-induced tubular cell death and acute kidney injury.
Li J; Xu Z; Jiang L; Mao J; Zeng Z; Fang L; He W; Yuan W; Yang J; Dai C
Kidney Int; 2014 Jul; 86(1):86-102. PubMed ID: 24451322
[TBL] [Abstract][Full Text] [Related]
35. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
[TBL] [Abstract][Full Text] [Related]
37. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
38. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway.
Yoshida S; Hong S; Suzuki T; Nada S; Mannan AM; Wang J; Okada M; Guan KL; Inoki K
J Biol Chem; 2011 Sep; 286(37):32651-60. PubMed ID: 21784859
[TBL] [Abstract][Full Text] [Related]
39. A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation.
Dalle Pezze P; Sonntag AG; Thien A; Prentzell MT; Gödel M; Fischer S; Neumann-Haefelin E; Huber TB; Baumeister R; Shanley DP; Thedieck K
Sci Signal; 2012 Mar; 5(217):ra25. PubMed ID: 22457331
[TBL] [Abstract][Full Text] [Related]
40. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
Breuleux M; Klopfenstein M; Stephan C; Doughty CA; Barys L; Maira SM; Kwiatkowski D; Lane HA
Mol Cancer Ther; 2009 Apr; 8(4):742-53. PubMed ID: 19372546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
